UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000063671
Receipt number R000072817
Scientific Title Changes in Vascular Endothelial-Related Biomarkers Before and After Nerandomilast Initiation and Their Association with Pulmonary Function
Date of disclosure of the study information 2026/11/18
Last modified on 2026/11/18 00:21:44

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Changes in Vascular Endothelial-Related Biomarkers Before and After Nerandomilast Initiation and Their Association with Pulmonary Function

Acronym

NERA-ENDO Study

Scientific Title

Changes in Vascular Endothelial-Related Biomarkers Before and After Nerandomilast Initiation and Their Association with Pulmonary Function

Scientific Title:Acronym

NERA-ENDO Study

Region

Japan


Condition

Condition

Fibrotic interstitial lung disease

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to evaluate changes in serum levels of syndecan-1 (SDC-1), soluble E-selectin (sE-selectin), and soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients with interstitial lung disease starting nerandomilast treatment and to examine their association with changes in forced vital capacity (FVC) over 6 months. Serum biomarker levels will be measured at baseline and at 3 and 6 months after treatment initiation. As a secondary objective, we will examine whether changes in these biomarkers during the first 3 months are associated with changes in FVC from baseline to 6 months.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The association between the absolute change in forced vital capacity (FVC, mL) from baseline to 6 months after nerandomilast initiation and changes in serum SDC-1, sE-selectin, and sVCAM-1 over the same period. This association will be assessed using the overall F-test in a multiple linear regression model including changes in all three biomarkers as independent variables.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

999 years-old >

Gender

Male and Female

Key inclusion criteria

1. Patients aged 18 years or older with fibrotic interstitial lung disease.
2. Patients who are considered eligible for nerandomilast treatment by their treating physician in routine clinical practice and are scheduled to initiate nerandomilast. Prior or concomitant treatment with nintedanib, pirfenidone, corticosteroids, or immunosuppressants is permitted.
3. Patients who have received sufficient information about the study and provided written informed consent.

Key exclusion criteria

1. Patients without an available serum sample obtained before nerandomilast initiation. Missing serum samples at 3 or 6 months after enrollment will be treated as missing data and will not result in exclusion from the study.
2. Patients unable to undergo pulmonary function testing. Missing pulmonary function test data at 3 or 6 months after enrollment will not result in exclusion from the study and will be treated as missing data.
3. Patients deemed unsuitable for study participation by the principal investigator or treating physician.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Yusuke
Middle name
Last name Nakamura

Organization

Dokkyo Medical University Hospital

Division name

Department of Pulmonary Medicine and Clinical Immunology

Zip code

321-0207

Address

880 Kitakobayashi, Mibu, Tochigi, JAPAN

TEL

0282872151

Email

nakamuyu@dokkyomed.ac.jp


Public contact

Name of contact person

1st name Yusuke
Middle name
Last name Nakamura

Organization

Dokkyo Medical University Hospital

Division name

Department of Pulmonary Medicine and Clinical Immunology

Zip code

321-0207

Address

880 Kitakobayashi, Mibu, Tochigi, JAPAN

TEL

0282-87-2151

Homepage URL


Email

nakamuyu@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University Hospital, Department of Pulmonary Medicine and Clinical Immunology

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Dokkyo Medical University Hospital Clinical Research Review Committee

Address

880 Kitakobayashi, Mibu, Tochigi, JAPAN

Tel

0282-86-1111

Email

none


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

獨協医科大学病院(栃木県)


Other administrative information

Date of disclosure of the study information

2026 Year 11 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2026 Year 09 Month 06 Day

Date of IRB

2026 Year 10 Month 23 Day

Anticipated trial start date

2026 Year 10 Month 23 Day

Last follow-up date

2031 Year 09 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

none


Management information

Registered date

2026 Year 11 Month 18 Day

Last modified on

2026 Year 11 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072817